Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | NVAX Novavax, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $10.11 +8.1% | $15.06 -2.2% |
| StockIQ Score | 65B- Moderate Risk: High | 35F Weak Risk: High |
| Technical | 71B | 13F |
| Fundamental | 70B | 35F |
| Growth | 68B- | 50C- |
| Fair Value | 43D | 38F |
| News | 92A+ | 50C- |
| Quality | 58C | 50C- |
| Risk | 40D | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
NVAX outperforms AAPG in every category. Its technical score of 85 is far stronger than AAPG’s 18, while its fundamental score of 70 also leads significantly over AAPG’s 35. NVAX’s investor rating is "Moderate," compared to AAPG’s "Weak," and its growth score of 68 is higher than AAPG’s 50. Only valuation scores are closer, but NVAX’s 43 still beats AAPG’s 38.